title: Design of cationic microspheres based on aminated gelatin for controlled release of peptide and protein drugs.
abstract: Two different types of cationized microspheres based on a native cationic gelatin (NGMS) and aminated gelatin with ethylendiamine (CGMS) were investigated for the controlled release of three model acidic peptide/protein drugs with different molecular weights (MWs) and isoelectric points (IEPs). Recombinant human (rh)-insulin (MW: 5.8 kDa, IEP: 5.3), bovine milk lactoalbumin, BMLA (MW: 14 kDa, IEP: 4.3), and bovine serum albumin (BSA MW: 67 kDa, IEP: 4.9) were used as model acidic peptide/protein drugs. The in vitro release profiles of these acidic peptide/protein drugs from NGMS and CGMS were compared and different periods of cross-linking were obtained. The slower release of these acidic peptide/protein drugs from CGMS compared with those from NGMS with cross-linking for 48 hr. was caused by the suppression of burst release during the initial phase. The degree of suppression of burst release of the three peptide/protein drugs during the initial phase by CGMS was in the following order: (rh)-insulin > BMLA > BSA. The release of insulin with a lower molecular weight from CGMS was particularly suppressed compared with the other two drugs with higher molecular weights in the initial phase. The control of the release rate of acidic peptide/protein drugs from gelatin microsphere can be achieved by amination of gelatin. Therefore, CGMS is useful for the controlled release of acidic peptide/ protein drugs.
authors.affiliation: School of Pharmacy, Hokkaido Phamaceutical University, Hokkaido, Japan. morimoto@hokuyakudai.ac.jp
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Morimoto
authors.forename: Sumio
authors.initials: S
authors.lastname: Chono
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kosai
authors.forename: Toshinobu
authors.initials: T
authors.lastname: Seki
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Tabata
mesh_terms: D000586:Amination; D002412:Cations / Q000737:chemistry; D003692:Delayed-Action Preparations; D015195:Drug Design; D005029:Ethylenediamines / Q000737:chemistry; D005780:Gelatin / Q000737:chemistry*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry; D007328:Insulin / Q000008:administration & dosage / Q000737:chemistry; D007768:Lactalbumin / Q000008:administration & dosage / Q000737:chemistry; D008863:Microspheres; D008970:Molecular Weight; D010455:Peptides / Q000008:administration & dosage*; D011506:Proteins / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000737:chemistry; D012235:Rhodamines / Q000737:chemistry; D012710:Serum Albumin, Bovine / Q000008:administration & dosage / Q000737:chemistry
chemical_list: D002412:Cations; D003692:Delayed-Action Preparations; D005029:Ethylenediamines; D007004:Hypoglycemic Agents; D007328:Insulin; D010455:Peptides; D011506:Proteins; D011994:Recombinant Proteins; D012235:Rhodamines; D012710:Serum Albumin, Bovine; D005780:Gelatin; D007768:Lactalbumin; C027755:rhodamine isothiocyanate